Dental Pulp Stem Cell Supernatant for Multifactorial Cancer Cachexia

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments for cancer cachexia, such as those using anamorelin, megestrol acetate, melatonin, and ostarine, are inadequate, and existing compositions containing extracellular vesicles from mesenchymal stem cells do not effectively address cachexia symptoms.

Innovation Solution

A culture supernatant derived from dental pulp-derived stem cells, containing microparticles such as exosomes, is administered to improve cancer cachexia symptoms by suppressing blood cytokines and enhancing hemocyte levels.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments (anamorelin, megestrol acetate, melatonin, ostarine) are used for cancer cachexia, then some symptomatic relief may be achieved, but the treatments are inadequate and do not effectively address the multifactorial nature of cachexia including weight loss, undernutrition, and anemia

Engineering Contradiction:
Improveeffectiveness of cachexia treatmentVSAvoidability to address multifactorial cachexia symptoms
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The culture supernatant of dental pulp-derived stem cells serves multiple functions simultaneously: it suppresses inflammatory cytokines (IL-6, TNF-α), improves nutritional status, corrects anemia by enhancing hemocyte levels, and reduces weight loss. This multi-functional approach addresses the multifactorial nature of cancer cachexia that conventional single-target treatments fail to resolve effectively.

Inventive Principle:
Principle #6Universality (Multi-functionality)

2Reliability

If extracellular vesicles from mesenchymal stem cells are administered, then some therapeutic effect is intended, but existing compositions do not effectively improve cachexia symptoms

Engineering Contradiction:
Improvecachexia symptom improvementVSAvoidavailability of effective composition
Core Design Contradiction:
ReliabilityVSEase of manufacture

Solution Approach 1:

The invention changes the source parameter of the extracellular vesicles from conventional mesenchymal stem cells to dental pulp-derived stem cells. This parameter change results in culture supernatant with enhanced therapeutic properties, specifically superior cytokine suppression capability and hemocyte enhancement effect, thereby effectively improving cachexia symptoms where previous compositions failed.

Inventive Principle:
Principle #35Parameter changes

3Reliability

If cytokine levels are suppressed to improve cachexia, then weight loss and undernutrition may be reduced, but the mechanism must be specific enough to avoid suppressing beneficial immune functions

Engineering Contradiction:
Improvesuppression of harmful cytokinesVSAvoidpotential immune suppression
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The culture supernatant of dental pulp-derived stem cells acts as an intermediary substance that mediates the suppression of harmful cytokines (IL-6, TNF-α) without directly inhibiting immune cell function. The supernatant contains bioactive factors that selectively modulate the cytokine environment, reducing the harmful inflammatory response while preserving beneficial immune surveillance and anti-tumor immunity.

Inventive Principle:
Principle #24Intermediary (Mediator)

Data Source

PatentEP4349348B1Agent for use in improving cancer cachexia and method for improving cancer cachexia
Publication Date: 2026.04.01 DEXON PHARM INC
  • EP4349348B1 patent drawingFigure 1~2
  • EP4349348B1 patent drawingFigure 3~4
  • EP4349348B1 patent drawingFigure 5~6

AI summary

An agent for improving cancer cachexia used for administration to a subject with cancer cachexia which is a composition containing a culture supernatant of dental pulp-derived stem cells and in which the culture supernatant contains microparticles derived from the dental pulp-derived stem cells is a novel agent for improving cancer cachexia; a method for improving cancer cachexia.